Our results support previous observations that incidental dose outside the target region is associated with reduced BCR in high-risk prostate cancer patients (18, 24, 45), providing further evidence for adapting the treatment volume for men with high-risk disease. The gene discussed is BCR; the disease is prostate carcinoma.